search
Back to results

The Bio-Inspired Artificial Pancreas for the Home (BiAP@home)

Primary Purpose

Diabetes Mellitus, Type 1

Status
Terminated
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
BiAP
ABC4D
Sponsored by
Imperial College London
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional device feasibility trial for Diabetes Mellitus, Type 1

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adults over 18 years of age
  • Type 1 diabetes confirmed on the basis of clinical features and a random c-peptide <200 pmol/L
  • Type 1 diabetes for greater than 1 year
  • Continuous subcutaneous insulin infusion for greater than 6 months
  • Structured education done (either 1:1 or group education)
  • HbA1c <10% (86mmol/mol)
  • A negative pregnancy test in female participants of childbearing age

Exclusion Criteria:

  • More than one episode of severe hypoglycaemia (defined as hypoglycaemia requiring 3rd party assistance) in the preceding year
  • Impaired awareness of hypoglycaemia (Gold score >4)
  • Pregnant or planning pregnancy
  • Breastfeeding
  • Enrolled in other clinical trials
  • Have active malignancy or under investigation for malignancy
  • Severe visual impairment
  • Reduced manual dexterity
  • Ischaemic heart disease
  • Anti-anginal medications
  • Regular use of paracetamol
  • Unable to participate due to other factors, as assessed by the Chief Investigator

Sites / Locations

  • Imperial College Clinical Research Facility

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

No Intervention

Experimental

Experimental

Arm Label

SAP, open-loop

BiAP, fixed bolus calculator

BiAP, ABC4D

Arm Description

Sensor augmented pump (combination of insulin pump and continuous glucose monitoring) (open-loop system)

Bio-inspired Artificial Pancreas (closed-loop system) with a fixed bolus calculator

Bio-inspired Artificial Pancreas (closed-loop system) with the Advanced Bolus Calculator for Diabetes (ABC4D)

Outcomes

Primary Outcome Measures

% time in target range defined as 3.9-10mmol/l
Interstitial blood glucose will be measured every 5 minutes via CGM for a period of six months

Secondary Outcome Measures

% time spent in euglycaemia (3.9-7.8mmol/l)
Interstitial blood glucose will be measured every 5 minutes via CGM for a period of six months
% time spent in hypoglycaemia (<3.9mmol/l)
Interstitial blood glucose will be measured every 5 minutes via CGM for a period of six months
% time spent in hypoglycaemia (<2.8mmol/l)
Interstitial blood glucose will be measured every 5 minutes via CGM for a period of six months
% time spent in hyperglycaemia (>10mmol/l)
Interstitial blood glucose will be measured every 5 minutes via CGM for a period of six months
% time spent in severe hyperglycaemia (<15mmol/l)
Interstitial blood glucose will be measured every 5 minutes via CGM for a period of six months
Mean sensor glucose
Interstitial blood glucose will be measured every 5 minutes via CGM for a period of six months
Glycaemic variability
Calculation using CGM data
Glycaemic risk as measured by LBGI and HBG
Calculation using CGM data
Closed loop error grid analysis
Calculation using CGM data
Glucose area under the curve
Calculation using CGM data
Insulin requirement in units/kg/hr
Calculation using average insulin delivered per hour and bodyweight
Hypoglycaemia awareness (Gold scores)
Quantitative Gold score questionnaire
Quality of life Questionnaire
Measured via validated questionnaire
Cost-effectiveness
Cost of equipment when compared with standard of care
Device usability
Measured via validated questionnaire
% time in closed loop control
Calculation using BiAP data
Severe hypoglycaemia
Calculation using CGM data
Diabetic ketoacidosis
Incidences of DKA
Sensor MAD%
Calculation using CGM data

Full Information

First Posted
November 7, 2018
Last Updated
March 29, 2022
Sponsor
Imperial College London
search

1. Study Identification

Unique Protocol Identification Number
NCT03740698
Brief Title
The Bio-Inspired Artificial Pancreas for the Home
Acronym
BiAP@home
Official Title
The Bio-Inspired Artificial Pancreas for the Home
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Terminated
Why Stopped
Technical issues
Study Start Date
February 1, 2021 (Actual)
Primary Completion Date
January 31, 2022 (Actual)
Study Completion Date
January 31, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Imperial College London

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of the study is to evaluate the safety and effectiveness of a closed-loop insulin delivery system (also known as an artificial pancreas) which is made up of three components that communicate with each other: A glucose sensor that measures glucose every 5 minutes A control algorithm that calculates the required insulin dose An insulin pump that delivers the insulin calculated
Detailed Description
In addition to assessing the closed-loop insulin delivery system on its own, the study aims to evaluate the system when combined with a personalised bolus calculator that adapts over time. Standard bolus calculators are widely used in type 1 diabetes self-management to calculate insulin boluses at mealtimes and are incorporated in all insulin pumps and in some glucose meters. A standard bolus calculator uses a generic formula taking into account the target glucose level, current glucose level, carbohydrate content of meal (grams), insulin: carbohydrate ratio (the amount of carbohydrate (grams) covered by 1 unit of insulin), insulin sensitivity factor (the reduction in blood glucose by 1 unit of insulin) and insulin-on-board (IOB, the remaining active insulin from the previous bolus). Some bolus calculators additionally consider parameters such as exercise, but all lack the ability to automatically adapt over time to respond to individual needs. Finally, the study aims to compare the closed-loop insulin delivery system to standard pump therapy (also known as an open-loop insulin delivery system) in combination with continuous glucose monitoring (referred to as sensor augmented pump). The Diabetes Technology group at Imperial College have developed a unique closed-loop insulin delivery system known as the Bio-inspired Artificial Pancreas (BiAP) and a personalised bolus calculator known as the Advanced Bolus Calculator for Diabetes (ABC4D). Overview of the complete closed-loop system (artificial pancreas) used in this study is as follows: A commercially available continuous subcutaneous glucose sensor (Dexcom G5 CGM system). The BiAP control algorithm implemented in a low-power handheld device (developed at Imperial College) An insulin infusion pump (Tandem t:slim) for insulin delivery. In one part of the study the closed-loop system will be evaluated in combination with: The ABC4D adaptive bolus calculator implemented in a smartphone (as an app) All the components will be tested together as a combined system.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 1

7. Study Design

Primary Purpose
Device Feasibility
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
This is a 3-way crossover open-label randomized controlled trial. Description of the three interventions for comparison are as follows: Sensor augmented pump (combination of insulin pump and continuous glucose monitoring) (open-loop system) Bio-inspired Artificial Pancreas (closed-loop system) with a fixed bolus calculator Bio-inspired Artificial Pancreas (closed-loop system) with the Advanced Bolus Calculator for Diabetes (ABC4D) The intervention in each arm will be assessed over 6 weeks with a minimum 2-week break in between each intervention. During the break participants will revert back to usual pump therapy.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
3 (Actual)

8. Arms, Groups, and Interventions

Arm Title
SAP, open-loop
Arm Type
No Intervention
Arm Description
Sensor augmented pump (combination of insulin pump and continuous glucose monitoring) (open-loop system)
Arm Title
BiAP, fixed bolus calculator
Arm Type
Experimental
Arm Description
Bio-inspired Artificial Pancreas (closed-loop system) with a fixed bolus calculator
Arm Title
BiAP, ABC4D
Arm Type
Experimental
Arm Description
Bio-inspired Artificial Pancreas (closed-loop system) with the Advanced Bolus Calculator for Diabetes (ABC4D)
Intervention Type
Device
Intervention Name(s)
BiAP
Intervention Description
The bio-inspired artificial pancreas (BiAP) system uses a control algorithm based on a mathematical model of beta-cell behaviour derived from physiological experiments, carried out by other groups, which have demonstrated how the beta cells in the pancreas produce insulin in people without diabetes. Utilising the data from these experiments it has been possible to implement the behaviour of the beta cell in software and we have used a simulator with 200 virtual patients to demonstrate the safety and efficacy of the algorithm. The data from the simulator have previously been published. The BiAP algorithm is implemented on a miniature silicon microchip within a portable handheld device, which interfaces the components of the artificial pancreas.
Intervention Type
Device
Intervention Name(s)
ABC4D
Intervention Description
The Advanced Bolus Calculator for Diabetes (ABC4D) is a novel, adaptive decision support algorithm based on case-based reasoning (CBR) providing real-time insulin advice through a smartphone application.
Primary Outcome Measure Information:
Title
% time in target range defined as 3.9-10mmol/l
Description
Interstitial blood glucose will be measured every 5 minutes via CGM for a period of six months
Time Frame
6 months
Secondary Outcome Measure Information:
Title
% time spent in euglycaemia (3.9-7.8mmol/l)
Description
Interstitial blood glucose will be measured every 5 minutes via CGM for a period of six months
Time Frame
6 months
Title
% time spent in hypoglycaemia (<3.9mmol/l)
Description
Interstitial blood glucose will be measured every 5 minutes via CGM for a period of six months
Time Frame
6 months
Title
% time spent in hypoglycaemia (<2.8mmol/l)
Description
Interstitial blood glucose will be measured every 5 minutes via CGM for a period of six months
Time Frame
6 months
Title
% time spent in hyperglycaemia (>10mmol/l)
Description
Interstitial blood glucose will be measured every 5 minutes via CGM for a period of six months
Time Frame
6 months
Title
% time spent in severe hyperglycaemia (<15mmol/l)
Description
Interstitial blood glucose will be measured every 5 minutes via CGM for a period of six months
Time Frame
6 months
Title
Mean sensor glucose
Description
Interstitial blood glucose will be measured every 5 minutes via CGM for a period of six months
Time Frame
6 months
Title
Glycaemic variability
Description
Calculation using CGM data
Time Frame
6 months
Title
Glycaemic risk as measured by LBGI and HBG
Description
Calculation using CGM data
Time Frame
6 months
Title
Closed loop error grid analysis
Description
Calculation using CGM data
Time Frame
6 months
Title
Glucose area under the curve
Description
Calculation using CGM data
Time Frame
6 months
Title
Insulin requirement in units/kg/hr
Description
Calculation using average insulin delivered per hour and bodyweight
Time Frame
6 months
Title
Hypoglycaemia awareness (Gold scores)
Description
Quantitative Gold score questionnaire
Time Frame
6 months
Title
Quality of life Questionnaire
Description
Measured via validated questionnaire
Time Frame
6 months
Title
Cost-effectiveness
Description
Cost of equipment when compared with standard of care
Time Frame
6 months
Title
Device usability
Description
Measured via validated questionnaire
Time Frame
6 months
Title
% time in closed loop control
Description
Calculation using BiAP data
Time Frame
6 months
Title
Severe hypoglycaemia
Description
Calculation using CGM data
Time Frame
6 months
Title
Diabetic ketoacidosis
Description
Incidences of DKA
Time Frame
6 months
Title
Sensor MAD%
Description
Calculation using CGM data
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adults over 18 years of age Type 1 diabetes confirmed on the basis of clinical features and a random c-peptide <200 pmol/L Type 1 diabetes for greater than 1 year Continuous subcutaneous insulin infusion for greater than 6 months Structured education done (either 1:1 or group education) HbA1c <10% (86mmol/mol) A negative pregnancy test in female participants of childbearing age Exclusion Criteria: More than one episode of severe hypoglycaemia (defined as hypoglycaemia requiring 3rd party assistance) in the preceding year Impaired awareness of hypoglycaemia (Gold score >4) Pregnant or planning pregnancy Breastfeeding Enrolled in other clinical trials Have active malignancy or under investigation for malignancy Severe visual impairment Reduced manual dexterity Ischaemic heart disease Anti-anginal medications Regular use of paracetamol Unable to participate due to other factors, as assessed by the Chief Investigator
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nick Oliver
Organizational Affiliation
Imperial College London
Official's Role
Principal Investigator
Facility Information:
Facility Name
Imperial College Clinical Research Facility
City
London
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
23851519
Citation
Georgiou P, Toumazou C. A silicon pancreatic Beta cell for diabetes. IEEE Trans Biomed Circuits Syst. 2007 Mar;1(1):39-49. doi: 10.1109/TBCAS.2007.893178.
Results Reference
background
PubMed Identifier
20144397
Citation
Oliver N, Georgiou P, Johnston D, Toumazou C. A benchtop closed-loop system controlled by a bio-inspired silicon implementation of the pancreatic beta cell. J Diabetes Sci Technol. 2009 Nov 1;3(6):1419-24. doi: 10.1177/193229680900300623.
Results Reference
background
PubMed Identifier
19444330
Citation
Kovatchev BP, Breton M, Man CD, Cobelli C. In silico preclinical trials: a proof of concept in closed-loop control of type 1 diabetes. J Diabetes Sci Technol. 2009 Jan;3(1):44-55. doi: 10.1177/193229680900300106.
Results Reference
background
PubMed Identifier
24956470
Citation
Herrero P, Pesl P, Reddy M, Oliver N, Georgiou P, Toumazou C. Advanced Insulin Bolus Advisor Based on Run-To-Run Control and Case-Based Reasoning. IEEE J Biomed Health Inform. 2015 May;19(3):1087-96. doi: 10.1109/JBHI.2014.2331896.
Results Reference
background
PubMed Identifier
22768892
Citation
Herrero P, Georgiou P, Oliver N, Johnston DG, Toumazou C. A bio-inspired glucose controller based on pancreatic beta-cell physiology. J Diabetes Sci Technol. 2012 May 1;6(3):606-16. doi: 10.1177/193229681200600316.
Results Reference
background

Learn more about this trial

The Bio-Inspired Artificial Pancreas for the Home

We'll reach out to this number within 24 hrs